Published in J Hepatol on January 29, 2008
"Second hit" models of alcoholic liver disease. Semin Liver Dis (2009) 1.12
Rodent models of alcoholic liver disease: of mice and men. Alcohol (2012) 1.11
Laboratory models available to study alcohol-induced organ damage and immune variations: choosing the appropriate model. Alcohol Clin Exp Res (2010) 1.01
Advances in alcoholic liver disease. Curr Gastroenterol Rep (2011) 0.98
Plasmin triggers a switch-like decrease in thrombospondin-dependent activation of TGF-β1. Biophys J (2012) 0.88
Osteopontin is an important mediator of alcoholic liver disease via hepatic stellate cell activation. World J Gastroenterol (2014) 0.81
Therapeutic potential of chinese herbal medicines in alcoholic liver disease. J Tradit Complement Med (2012) 0.79
Exacerbation of alcohol-induced oxidative stress in rats by polyunsaturated Fatty acids and iron load. Indian J Pharm Sci (2011) 0.79
Transitional Remodeling of the Hepatic Extracellular Matrix in Alcohol-Induced Liver Injury. Biomed Res Int (2016) 0.78
High-density real-time PCR-based in vivo toxicogenomic screen to predict organ-specific toxicity. Int J Mol Sci (2011) 0.78
Multiplex transcriptional analysis of paraffin-embedded liver needle biopsy from patients with liver fibrosis. Fibrogenesis Tissue Repair (2012) 0.76
Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis. Oncol Lett (2013) 0.76
Effect of multiple binge alcohol on diet-induced liver injury in a mouse model of obesity. Nutr Diabetes (2015) 0.75
Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology (2003) 4.10
Unplanned admissions to two Sydney public hospitals after naltrexone implants. Med J Aust (2008) 3.98
Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet (2007) 3.62
Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem (2005) 2.99
Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci U S A (2006) 2.65
Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology (2007) 2.36
Allosteric disulfide bonds. Biochemistry (2006) 2.32
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol (2012) 2.31
T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells. Hepatology (2006) 2.30
3-dimensional imaging of collagen using second harmonic generation. J Struct Biol (2003) 2.30
Disulfide exchange in domain 2 of CD4 is required for entry of HIV-1. Nat Immunol (2002) 2.28
Patient and graft survival after liver transplantation for hereditary hemochromatosis: Implications for pathogenesis. Hepatology (2004) 2.17
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology (2014) 2.12
Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology (2011) 2.05
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology (2009) 1.99
Evidence for activation of tissue factor by an allosteric disulfide bond. Biochemistry (2006) 1.99
Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology (2011) 1.89
Hepatocyte entry leads to degradation of autoreactive CD8 T cells. Proc Natl Acad Sci U S A (2011) 1.89
Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A (2003) 1.86
Arsenical-based cancer drugs. Cancer Treat Rev (2007) 1.78
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci (Lond) (2009) 1.66
Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med (2006) 1.59
Approaching the promise of operational tolerance in clinical transplantation. Transplantation (2011) 1.54
Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis (2004) 1.54
The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J Clin Invest (2004) 1.53
Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. Liver Transpl (2009) 1.50
Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology (2007) 1.49
Naïve CD8 T cell activation by liver bone marrow-derived cells leads to a "neglected" IL-2low Bimhigh phenotype, poor CTL function and cell death. J Hepatol (2012) 1.48
Hereditary lysozyme amyloidosis: spontaneous hepatic rupture (15 years apart) in mother and daughter. role of emergency liver transplantation. Liver Transpl (2006) 1.46
Protein-protein interaction between Fli-1 and GATA-1 mediates synergistic expression of megakaryocyte-specific genes through cooperative DNA binding. Mol Cell Biol (2003) 1.44
Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol (2002) 1.34
The liver: a special case in transplantation tolerance. Semin Liver Dis (2007) 1.33
Pathogenesis and management of alcoholic hepatitis. J Gastroenterol Hepatol (2003) 1.28
A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology (2008) 1.27
Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology (2005) 1.25
The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J (2010) 1.24
Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology (2004) 1.24
Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. Addiction (2006) 1.24
SMART amplification maintains representation of relative gene expression: quantitative validation by real time PCR and application to studies of alcoholic liver disease in primates. J Biochem Biophys Methods (2003) 1.23
Predictors of relapse to harmful alcohol after orthotopic liver transplantation. Alcohol Alcohol (2006) 1.19
Post-translational control of protein function by disulfide bond cleavage. Antioxid Redox Signal (2013) 1.18
An overview of the patterns of prescription opioid use, costs and related harms in Australia. Br J Clin Pharmacol (2014) 1.16
Role of primary intrahepatic T-cell activation in the 'liver tolerance effect'. Immunol Cell Biol (2002) 1.16
Cross-strand disulphides in cell entry proteins: poised to act. Bioessays (2004) 1.15
Search for allosteric disulfide bonds in NMR structures. BMC Struct Biol (2007) 1.15
Intrahepatic immunity: a tale of two sites? Trends Immunol (2005) 1.11
Intrahepatic murine CD8 T-cell activation associates with a distinct phenotype leading to Bim-dependent death. Gastroenterology (2008) 1.11
Pathogenesis of alcohol-induced liver disease: classical concepts and recent advances. J Gastroenterol Hepatol (2011) 1.10
Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood (2003) 1.10
Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Lett (2008) 1.10
Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. Clin Infect Dis (2013) 1.09
Liver fibrosis: a balance of ACEs? Clin Sci (Lond) (2007) 1.08
Intrahepatic gene expression in human alcoholic hepatitis. J Hepatol (2006) 1.08
Gene expression profiling of alcoholic liver disease in the baboon (Papio hamadryas) and human liver. Am J Pathol (2003) 1.08
Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta (2004) 1.06
Two lymph nodes draining the mouse liver are the preferential site of DC migration and T cell activation. J Hepatol (2012) 1.05
Cytokine-dependent bystander hepatitis due to intrahepatic murine CD8 T-cell activation by bone marrow-derived cells. Gastroenterology (2002) 1.05
Role of thrombospondin-1 in control of von Willebrand factor multimer size in mice. J Biol Chem (2004) 1.05
Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. J Hepatol (2010) 1.04
Mitochondria as cancer drug targets. Trends Mol Med (2004) 1.04
Critical importance of the cell system when studying tissue factor de-encryption. Blood (2008) 1.04
Risk factors for hepatitis C infection and perception of antibody status among male prison inmates in the Hepatitis C Incidence and Transmission in Prisons Study cohort, Australia. J Urban Health (2004) 1.03
A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell (2003) 1.03
Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology (2009) 1.03
Fibroblast activation protein and chronic liver disease. Front Biosci (2008) 1.03
Evidence for a domain-swapped CD4 dimer as the coreceptor for binding to class II MHC. J Immunol (2006) 1.01
Unplanned pregnancy and contraceptive use in women attending drug treatment services. Aust N Z J Obstet Gynaecol (2012) 1.00
Transcriptome analyses and biofilm-forming characteristics of a clonal Pseudomonas aeruginosa from the cystic fibrosis lung. J Med Microbiol (2008) 1.00
Beta 2 glycoprotein I is a substrate of thiol oxidoreductases. Blood (2010) 0.99
Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-α. FEBS J (2011) 0.99
Control of mature protein function by allosteric disulfide bonds. Antioxid Redox Signal (2010) 0.98
Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. Med J Aust (2010) 0.98
Vitamin D replacement for cirrhosis-related bone disease. Nat Clin Pract Gastroenterol Hepatol (2006) 0.98
Spontaneous acceptance of mouse kidney allografts is associated with increased Foxp3 expression and differences in the B and T cell compartments. Transpl Immunol (2011) 0.98
Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol (2010) 0.98
The von Willebrand factor-reducing activity of thrombospondin-1 is located in the calcium-binding/C-terminal sequence and requires a free thiol at position 974. Blood (2002) 0.97
Novel differential gene expression in human cirrhosis detected by suppression subtractive hybridization. Hepatology (2003) 0.97
Issues with recruitment to randomised controlled trials in the drug and alcohol field: a literature review and Australian case study. Drug Alcohol Rev (2008) 0.97
Structural requirements for catalysis, expression, and dimerization in the CD26/DPIV gene family. Biochemistry (2003) 0.97
Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl (2013) 0.97
Noninvasive imaging of cell death using an Hsp90 ligand. J Am Chem Soc (2011) 0.96
Redox control on the cell surface: implications for HIV-1 entry. Antioxid Redox Signal (2003) 0.96